reviewTop 1% cited
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The Lancet Oncology · 2016 · Vol. 17(12) · pp. e542–e551
Geoffrey T. Gibney✉(MedStar Georgetown University Hospital)Louis M. Weiner(MedStar Georgetown University Hospital)Michael B. Atkins(MedStar Georgetown University Hospital)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune ResponsesImmunotherapyBiomarkerMedicineMultiplexMelanomaOncologyImmune checkpointClinical trialPD-L1Biomarker discovery
MeSH terms
HumansImmunohistochemistryImmunotherapyNeoplasmsBiomarkersLymphocytes, Tumor-InfiltratingTumor MicroenvironmentCell Cycle CheckpointsB7-H1 Antigen
Citations
1,657
FWCI
57.68
field-weighted impact
References
77
Percentile
100%
vs. same field & year
Citations per year
Cited by
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Frontiers in Pharmacology · 2017 · 465 citations
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature reviews. Cancer · 2019 · 2,306 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 4,300 citations
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Nature Reviews Drug Discovery · 2019 · 3,331 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Journal of Clinical Oncology · 1999 · 2,025 citations
Oncology Meets Immunology: The Cancer-Immunity Cycle
Immunity · 2013 · 6,760 citations
Innate and adaptive immune cells in the tumor microenvironment
Nature Immunology · 2013 · 4,168 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science · 2015 · 7,864 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Clinical Cancer Research · 2014 · 2,320 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.